Category: Articles

How to Read the Medical Device Patent Landscape Before Entering a New Therapeutic Category

The FTO-Landscape Sequence: Why the Order You Run These Two Searches In Changes the Answer You Get

Whitespace Analysis vs. Patent Landscape Analysis: What Is the Difference and Which One Does Your R&D Team Actually Need?

When a Clean FTO Opinion Is Not Enough: The Four Situations That Require a Follow-Up Search

FTO in Switzerland After the 2027 Patent Act Reform: What Pharma and MedTech Companies Need to Clear Before Launch

Denmark’s Clean Energy Patent Landscape: What the IP Picture Looks Like for Wind, Hydrogen, and Heat Pump Innovation

Japan’s Life Sciences Patent Landscape: What the Post-Dapagliflozin Plausibility Standard Means for Pharma R&D Strategy

China’s CNIPA 2026 Guidelines Changed How Patents Are Examined. Has Your Competitive Landscape Caught Up?

Your Germany FTO May No Longer Be Enough: What the UPC’s Long-Arm Jurisdiction Means for Pharma and MedTech Product Launches

The UK Life Sciences Patent Landscape in 2026: What the Dapagliflozin Ruling, Patent Cliff and MHRA Reforms Mean for Your IP Strategy

Load More